Johnson Financial Group Inc. Invests $2.12 Million in Gilead Sciences, Inc. $GILD

Johnson Financial Group Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,791 shares of the biopharmaceutical company’s stock, valued at approximately $2,121,000.

Several other large investors have also bought and sold shares of the company. Aviva PLC lifted its position in shares of Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after acquiring an additional 59,782 shares during the last quarter. Life Cycle Investment Partners Ltd acquired a new position in shares of Gilead Sciences in the 4th quarter worth $1,418,000. NBC Securities Inc. grew its holdings in shares of Gilead Sciences by 150.3% in the 4th quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock worth $2,105,000 after acquiring an additional 10,296 shares during the last quarter. Flputnam Investment Management Co. raised its position in shares of Gilead Sciences by 66.5% during the fourth quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company’s stock worth $12,978,000 after purchasing an additional 42,243 shares during the period. Finally, Harvest Fund Management Co. Ltd lifted its holdings in shares of Gilead Sciences by 14.4% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company’s stock valued at $13,075,000 after purchasing an additional 13,385 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on GILD shares. Daiwa Securities Group decreased their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Barclays reduced their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Twenty-four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Price Performance

Shares of GILD opened at $147.60 on Thursday. The company has a market capitalization of $183.02 billion, a price-to-earnings ratio of -55.28 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The business’s 50-day moving average is $131.21 and its 200-day moving average is $136.51.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period last year, the company posted $2.01 earnings per share. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. Equities research analysts expect that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the sale, the chief financial officer directly owned 165,646 shares in the company, valued at approximately $22,918,780.56. This trade represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the sale, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 82,000 shares of company stock valued at $10,837,860 in the last quarter. Company insiders own 0.30% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating on Gilead, supporting the bullish view that the company’s recent momentum can continue. BMO Capital reaffirms Buy rating
• Positive Sentiment: Zacks Research raised estimates for third-quarter 2026 EPS to $1.93 from $1.84, fourth-quarter 2026 EPS to $2.14 from $2.07, and full-year 2027 EPS to $9.30 from $9.11. It also lifted estimates for parts of 2027, indicating improving expectations for near-term earnings. Gilead Sciences analyst estimates
• Positive Sentiment: Investors remain focused on Gilead’s expanding HIV portfolio. Biktarvy continues to anchor sales, while Yeztugo and additional pipeline programs could create new treatment and prevention opportunities. The company’s latest reported revenue also increased 10.6% year over year to $7.8 billion, exceeding expectations. Gilead’s expanding HIV portfolio
• Positive Sentiment: Gilead’s quarterly dividend of $0.82, equivalent to $3.28 annually, provides ongoing income support and reinforces its appeal to defensive and healthcare-focused investors.
• Neutral Sentiment: Zacks reduced estimates for first-quarter 2028 EPS to $2.14 from $2.21, second-quarter 2028 EPS to $2.27 from $2.33, and full-year 2028 EPS to $9.58 from $10.00. These cuts temper the otherwise positive near-term revisions and suggest some uncertainty about longer-term growth.
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares, while CFO Andrew Dickinson sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may modestly weigh on sentiment.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.